Angiolutions has announced the appointment of four internationally recognised vascular and endovascular specialists to its medical board. The new board will support the company as it advances development of its investigational A3-Shield system, a first-in-class implant designed to treat abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves.
The Angiolutions medical board brings together leading physicians from the USA and Europe with extensive clinical, scientific and translational expertise in vascular surgery, endovascular therapies and aortic disease management. The inaugural members are:
- Mark A Farber (University of North Carolina at Chapel Hill [UNC], Chapel Hill, USA)
- Tilo Kölbel (University Medical Center Hamburg, Hamburg, Germany)
- Hubert Schelzig (University Medical Center Düsseldorf, Düsseldorf, Germany)
- Peter Schneider (University of California, San Francisco [UCSF], San Francisco, USA)
“We are proud to welcome this outstanding group of physicians to the Angiolutions medical board,” said Isabel N. Schellinger, co-founder and CEO of Angiolutions. “Their collective experience in vascular and endovascular care will be invaluable as we continue to develop the A3-Shield system and generate clinical evidence for a new treatment approach in patients with small AAAs. By working closely with leading experts in the field, we aim to accelerate our mission to offer patients an earlier therapeutic option.”
The medical board will provide strategic clinical guidance across product development, clinical investigation and future adoption pathways as Angiolutions extends its clinical programme. Its members will help inform Angiolutions’ efforts to address what the company has identified as a major unmet need in AAA care: the lack of an active treatment option for patients with small aneurysms who are not eligible for conventional repair.
“Bringing together leading experts from renowned centers in the US and Europe is an important step for Angiolutions,” said Uwe Raaz, co-founder and CEO of Angiolutions. “Their insights will be of utmost importance in shaping clinical strategy as we work to redefine how abdominal aortic aneurysms can be treated at an earlier stage.”
